Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma: further explanation of a dose-escalating pilot study conducted primarily to consider the safety of this pharmacological modification.

摘要

Madam, We would like to thank Mangano et al. for taking an interest in our article, which, was the first publication on the use of the novel iron-chelating agent CP94 topically in humans being treated with photodynamic therapy (PDT). As clearly stated in the original article (Introduction p. 388, Materials and methods p. 388-9 and Discussion p. 391-2) the primary purpose of this pilot study was to ascertain the safety and feasibility of this PDT pharmacological treatment modification. As a result the study design was very carefully considered and a dose-escalating pilot study conducted (Materials and methods p. 388-9), where the safety of our patients (in this the first clinical investigation of this novel pharmacological modification - the addition of CP94 to dermatological PDT) was paramount. Patients were assigned to each study group in strict order of recruitment at each centre and the CP94 dose was not increased until all investigators were satisfied that it was safe to do so.